申请人:Ajinomoto Co., Inc.
公开号:EP1323711A1
公开(公告)日:2003-07-02
Specific phenylalanine derivatives or pharmaceutically acceptable salts thereof have an antagonistic effect on the α4 integrins and, therefore, are usable as therapeutic agents or preventive agents for diseases in which α4 integrin-depending adhesion process participates in the pathology, such as inflammatory diseases, rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus, multiple sclerosis, Sjögren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular diseases, arterial sclerosis, restenosis, tumor proliferation, tumor metastasis and transplantation rejection.
特定的苯丙氨酸衍生物或其药学上可接受的盐类对 α4 整合素具有拮抗作用,因此可作为治疗剂或预防剂用于治疗 α4 整合素依赖性粘附过程参与病理的疾病、如炎症性疾病、类风湿性关节炎、炎症性肠病、系统性红斑狼疮、多发性硬化症、Sjögren's 综合征、哮喘、牛皮癣、过敏、糖尿病、心血管疾病、动脉硬化、再狭窄、肿瘤增殖、肿瘤转移和移植排斥反应。